



ASX AND MEDIA RELEASE

Michael Aldridge to present at healthcare conference

BRISBANE, Australia, 8 September 2005: Peplin Limited (ASX:PEP) announced its Managing Director and CEO Michael Aldridge would today present at the Southern Cross Equities' DNA, Devices & Dealers 2005 conference in Sydney.

The presentation is titled "Evaluating bio-risk and bio-return" and draws on Mr Aldridge's 10 years' experience as a healthcare investment banker in Europe and North America prior to joining Peplin in 2003 as Managing Director and CEO.

It presents a general analysis of the factors impacting on risk and return in the discovery and development of human therapeutic products and extends that analysis to Peplin's risk profile and return opportunities.

The conference program and details are available at:
www.asx.com.au/investor/industry/biotech/seminars.htm.

A copy of the presentation is available from Peplin's website at www.peplin.com under the investor presentation tab within the investor information section.

ENDS

Further information:

Michael Aldridge
Managing Director & CEO
Tel: 07-3250 1200
michael.aldridge@peplin.com

ABOUT PEPLIN

Peplin is focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Its lead compound is PEP005, the first in a new class of investigational agents. Peplin's lead product is PEP005 Topical, which is being studied in phase IIa clinical trials for the treatment of actinic keratosis (AK) (a pre-cancerous lesion) and non-melanoma skin cancer (NMSC). PEP005 Topical works by a powerful mode of action, directly killing most cancer cells and then recruiting and activating the local immune system to clean-up these dead cancer cells and kill any remaining cancer cells. PEP005 Topical is potentially a rapidly acting and cosmetically attractive non-surgical treatment for AK and NMSC. Peplin's product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin's earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intracavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 Topical and other oncology applications of PEP005. Its research portfolio of EPUFA compounds opens additional potential opportunities in cancer and pain.

Market opportunity

AKs are the most common pre-cancerous skin lesions worldwide and the treatment of AKs is the most common dermatologic procedure performed in the out-patient setting.

Based on a 2001 study, in the US each year there are 3.7 million office visits and about 5.2 million procedures for AK. According to the American Academy of Dermatology AK affects more than 10 million Americans. The worldwide prevalence of AK is highest in Australia. AKs typically occur on sun damaged skin of Caucasians older than 40 years.

NMSC is the most common form of cancer worldwide. Peplin is developing PEP005 Topical to address the highly attractive and significant global market opportunity for non-surgical approaches to the treatment of AK and NMSC.